Skip to content

Announcing our partnership with Serosep Ltd.

Thomas Beuls | Press Release | 19/04/2018

We're excited to announce today our partnership with Serosep Ltd.,  a leading global manufacturer of molecular solutions for clinical laboratories. In the partnership, we will add the Serosep EntericBio assay range to our platform FastFinder. 

This will allow existing and new EntericBio customers to benefit from standardized and simplified diagnostic interpretation supported by artificial intelligence and automation.

Serosep has earned a reputation of excellence in the clinical microbiology market for its class leading EntericBio solution for molecular enteric testing and its class leading support. The EntericBio system and assay range have obtained a strong track record in this market due to the innovative system and assay menu.

“FastFinder truly enables Serosep and our end-users to standardise and automate results analysis on the EntericBio system. Our customer-driven philosophy is to provide innovative products and best-in-class, real-time support to our customers so that their service is never compromised. Modernising & automating the analysis of our tests is a key part of this philosophy.” said David Clancy, Molecular Diagnostics Manager at Serosep ltd.

“Serosep has achieved impressive success with their EntericBio assays since their launch in 2012” said Dr. Tom Martens, Chief Commercial Officer at UgenTec, “we’re excited to help them accelerate and simplify their sales efforts by adding their assays to our FastFinder qPCR analysis platform”.

For more information visit:

Boston, San Francisco, Stockholm – January 12, 2023